用于人體治療藥物的 ClinGuide CRISPR sgRNA
20 多年來，安捷倫為客戶提供開發(fā)、生產(chǎn)、過程檢測、原料分析、原料藥放行和穩(wěn)定性測試解決方案。安捷倫開發(fā)分析方法和 RNA 合成生產(chǎn)工藝，可針對您特定的向導 RNA 優(yōu)化純度和產(chǎn)率。
- 寡核苷酸 GMP 生產(chǎn)
產(chǎn)品詳細信息
- 與階段相適應的嚴格質量體系包括 cGMP 標準和質量源于設計方法
- 與質譜兼容的高分辨率雜質分析方法有助于確保您的 CRISPR 分子具有高純度
- 位于科羅拉多州的兩個 cGMP 工廠可生產(chǎn)多種產(chǎn)品，并為多個項目提供支持，幫助您無縫轉入生產(chǎn)階段
- 由擁有 20 年以上經(jīng)驗的科學家組成的專家團隊，為多個臨床和商業(yè)項目的開發(fā)提供支持
- 與經(jīng)驗豐富的伙伴合作，幫助您獲得長期成功
- 項目經(jīng)理協(xié)調跨職能團隊，以明確了解您的要求并確保項目成功完成
- 重要資料
-
Agilent ClinGuide CRISPR sgRNA for Human Therapeutics
Accelerate the clinical success of therapeutic gene editing programs.
- 宣傳單頁
- English
- 2023 年 10 月 12 日
- 1.12 MB
Accelerate Your Journey from Clinic to Market
Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs
- 產(chǎn)品樣本
- English
- 2023 年 12 月 28 日
- 3.19 MB
視頻
Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing.
- Agilent to Acquire North American CDMO BIOVECTRA
- 2024 年 7 月 22 日
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.
- 2022 年 12 月 5 日